AGP Executive Report
Last update: 2 hours agoFDA & Diagnostics: A key FDA genetics panel voted in favor of the Galleri multi-cancer early detection test, backing safety unanimously and effectiveness by a narrower margin, for adults 50+ as an add-on to existing screening. Cancer Research & Trials: The IMS meeting wrapped with MRD-guided myeloma strategies, including updated CEPHEUS results supporting daratumumab quadruplet benefit, plus new CAR T safety and real-world performance updates. Clinical Development Rules: The FDA finalized a direct rule recognizing non-animal testing methods for nonclinical safety work, and launched an Expedited IND Pilot to speed first-in-human timelines via qualified research institution pairs. NIH Research Integrity: NIH plans a roughly $174M, five-year push to expand replication and reproducibility studies. AI Security in Healthcare Tech: As rogue AI agents raise cybersecurity alarms, Nvidia unveiled an “Open Agent Safety Platform” aimed at keeping agents contained. Biotech Deals & Pipeline: Merck secured global rights to a KRAS G12D inhibitor deal worth up to $2.13B, while Vyriad began first-in-human dosing of in-body CAR T via lentiviral VV169. New Drug Approvals: FDA cleared Lilly’s Olumiant for pediatric severe alopecia areata and AbbVie’s JUVMO for Parkinson’s, adding mechanistically distinct options.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Strategic Role of Innovative Lab Informatics Solution for Enabling Smarter R&D in Pharma]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/28906698-945872791-share-image-200x200.png)
